February 18, 2020

First patient enrolls in STEMI DTU randomized controlled FDA trial; study aims to further demonstrate Impella’s safety and effectiveness

Abiomed is a previous MLSC Tax Incentive awardee

Kudos to Danvers, MA-based Abiomed which recently announced the first U.S. patients treated with its minimally invasive, forward flow heart pump.

Abiomed is a previous awardee of the MLSC’s Tax Incentive Program. The program offers tax incentives to companies engaged in life sciences research and development, commercialization, and manufacturing in Massachusetts in order to expand life sciences-related employment opportunities and promote health-related innovations in the life sciences.